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eslie Miller, MD, FACC
ashington, DC
n increasing percentage of patients who are listed for a
eart transplant either present initially with such advanced
eart failure or deteriorate after listing that they are essen-
ially refractory to even intravenous inotrope and/or vasodi-
ator therapy. These patients have been increasingly man-
ged with mechanically circulatory support in the form of
entricular assist devices (VAD) until a donor heart is
dentified, also known as a “bridge to transplant.” The
ardiac Transplant Research Database has shown that
urrently more than one-third of all patients undergoing
eart transplantation are being supported with a VAD at
he time of transplantation. The first-generation devices
ere effective in supporting the circulation, but were asso-
iated with significant complications such as infection,
leeding, and organ failure caused by the severity of the
See page 264
atient’s condition (renal and hepatic dysfunction, malnu-
rition, and coagulation abnormalities) at the time of im-
lant. That led physicians to keep the patients listed at the
ighest priority status for transplant and to use the first
onor identified early after device implantation in hopes of
inimizing complications of the devices. However, that
trategy was found to be associated with significant mor-
idity and mortality after transplantation because patients
ften developed nosocomial infections caused by indwelling
atheters, malnutrition, and muscle weakness, with up to
ne-third of patients not surviving to transplantation. Over
ime, improvements in the durability and design of the
ADs, coupled with improved management of these pa-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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nd research support from Thoratec Corp., and is on the advisory boards of Thoratec
nd Heartware.ients, led to an extensive experience with successful hospital
ischarge and outpatient management for periods of
onths to years, and significant recovery of functional
tatus. This experience has led to the current approach in
ost centers of delaying relisting the patient for transplan-
ation until they have recovered physical condition and are
table, usually a period of 1 to 3 months. Mechanical
upport of the circulation allowed such progressive exercise
nd rehabilitation that VAD patients now are often the very
est candidates for heart transplantation because they are
he best conditioned.
The paper by Patlolla et al. (1) in this issue of the Journal
s the largest review of the long-term impact on mortality
ssociated with the use of VADs in patients awaiting heart
ransplantation, or “bridge to transplant.” The investigators
sed the United Network for Organ Sharing (UNOS)
atabase and included all patients who underwent trans-
lantation over a 9-year period from 1995 to 2004. A total
f 11,336 patients were included, with 1,887 of those, or
6.5%, having had pre-transplantation VAD support. The
tudy wisely divided the patients with VAD support into
hose with the more recent intracorporeal design versus the
lder extracorporeal types of devices. Hazard ratios (HRs)
or mortality were then calculated over a 5-year period
ost-transplantation for the 2 types of VADs, with out-
omes compared with the 9,455 patients who were listed as
tatus 1, but did not have mechanical circulatory support.
The investigators found a small but significant increase in
isk (HR: 1.2) at 6 months post-transplantation for those
eceiving intracorporeal VADs, but this risk was reduced to
nly 1.1 (10%) over the next 4 years until the final period of
bservation at 5 years, when it again increased to an HR of
.2. There was a significantly greater risk for those sup-
orted with the uncommonly used earlier generation of
xtracorporeal VADs at 6 months (HR: 1.9). It is of note
hat this increase in risk was also lost for the time between
months and 5 years, when the risk was shown to again be
ven higher (HR: 2.93).
The questions raised by these data include whether there
s a direct cause-and-effect relationship between VAD use
nd the increased mortality seen 5 years after transplanta-
ion, and if there is such an association, what is the cause. It
ould be argued that the only direct correlation between
re-transplantation VAD use and mortality would be ex-
ected to be in the immediate perioperative period, and
erhaps the first 6 months if the VAD patients were in fact
icker pre-transplantation and at higher risk for the trans-
lantation procedure. This is in fact what the investigators
ound in their analysis. An alternative hypothesis to explain
he increased risk is that VAD use, because of either
equired blood transfusion or the blood–device interface,
eads to immune activation and allosensitization, which
ould be associated with an increased risk of rejection
nd the need for increased immunosuppression post-
ransplantation and mortality risk. However, the Interna-
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eport has shown that there is no correlation between VAD use
nd an increase in rejection episodes post-transplantation
2). The leading causes of death long-term in heart transplant
ecipients are primarily cardiac allograft vasculopathy and
alignancy. To date, there has been no reported association
etween the use of VADs and either of these complications,
nd the most recent International Society for Heart and Lung
ransplantation Registry has shown that VAD use pre-
ransplantation is not associated with a secondary increase in
ortality at 5 years (2). The failure to show any significant
ifference in survival between 6 months and 4 years after
ransplant raises doubt about the basis and importance of the
% difference noted at year 5. It seems that the difference is not
linically significant, as the difference was 0% and 1% in the 2
receding years (3 and 4) and only 2% at 5 years.
The investigators interpret these data to suggest that the
se of VADs in stable UNOS status 1 patients is not
arranted because of the small (questionably clinically
elevant) increased mortality risk at the 2 time points noted.
iven the evolution in the management of the VAD
atients over time, it may be of value to see the data broken
ut by era, rather than by duration of follow-up. The
utcomes with medical therapy of status 1 patients with and
ithout VAD support have improved over the past 5 years
2), and a more recent examination of the data would be
elpful in determining whether the observations made are
ccurate in the current era.
The investigators acknowledge that the findings may not
pply to the newest generation of continuous-flow devices,
hich have been shown to have significantly better survival
nd quality of life and significantly lower adverse events than
he previous generation of pulsatile devices (3). The survival
ith the latest generation of continuous-flow devices may
e as high as 75% at 1 year, with little decrease by year 2.
hese improved outcomes may lead to loss of the increased
isk of VAD-supported patients compared with status 1
atients supported medically at 6 months and much later
ost-transplant by Patlolla et al. (1) The only way to
bjectively test this question is with a randomized trial, but
any patients initially assigned to medical therapy may
eteriorate and require cross-over to receive a VAD, and the
ime on the waiting list may vary considerably for patients in
ither assigned therapy, making direct comparison of out-
omes and complications difficult. A large cohort would be
equired to adequately power the study.
The question of whether the data presented suggest that
he risk for stable status 1 patients to undergo semielective
AD implant is too high is also open to debate. Some
atients can be well supported with intravenous inotropes
or a period of time, but there is an inherent risk of
nfection, proarrhythmia, and other complications, and
here are several reports of increased mortality in patients
upported with inotropes compared with VADs pre-
ransplantation (4,5). The UNOS database showed that 516
atients, or 20% of the 2,258 de novo patients listed as
4tatus 1A for a heart transplant between 1999 and 2006,
ied or were removed from the list for worsening condition
n the absence of mechanical circulatory support (6,7). One
nterpretation of these data is that use of VADs in a good
ercentage of these patients may have prevented a number
f those deaths or removals. There is also difficulty is
ssuming that the mortality risk of semistable status 1
atients would be the same as for those who have undergone
ypically urgent if not emergent VAD implantation as a
ridge to transplant to date. Recently, a risk stratification
ystem has been reported that identified patients at highest
isk for in-hospital death with VAD implant when used as
n alternative to transplantation or destination therapy (8).
his risk score has not been validated for bridge to trans-
lant patients, but the complications associated with VAD
se are exactly the same for bridge to transplant and
estination therapy, suggesting that the risk score would
ikely be valid for either indication. The score was based on
re-operative laboratory values and suggests that despite
imilar low ejection fraction and blood pressure, and other
emographics, those with the lowest risk had a 90% survival
o hospital discharge and 84% survival at 1 year. Equally
mportant is that it was able to identify patients with a
rohibitive risk at the time of planned implantation.
The study by Patlolla et al. (1) has raised some important
uestions about the impact of VAD use in patients awaiting
ransplantation. In this era of expanding health care costs, it
s important to look closely at the therapies now being
pplied to patients with advanced heart failure and to ask
ritical questions about their impact on survival, adverse
vents, and quality of life, as well as the cost-effectiveness of
therapy. The new generation of continuous-flow devices
as now been shown to provide much better outcomes than
revious pulsatile design devices, and it will be important in
he future to compare the outcomes with these devices to
he current cost and mortality of those managed without
echanical circulatory support (9). These trials will likely be
orthcoming in the near future.
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